

1/1 pie ædnin 0/510119

DT04 Rec'd PCT/PTO 0 4 OCT 2004

W.I.P.O. P.O. Box 18 CH 1211 Geneva 20 Switzerland

By fax and mail:

Your ref.

The Hague, 2 September 2004

Our ref.

P207556PCT BSW/ja

Re:

International Patent Application No. PCT/NL03/00254

Applicant: Leiden University Medical Center

Dear Madam, Sir,

With reference to Rule 92bis.1(a)(ii), the applicant herewith request deletion of Robert S. Mittler as an inventor and for the US inventor/applicant form the aboveidentified International Application.

The reason for this deletion is that Mr. Mittler contributions as inventor relate solely to those aspects of the invention that concern the 4-1BB molecule and the therapeutic use of agonists of this molecule. However, during preliminary examination the applicant has amended the claims to overcome novelty and inventive step objections based inter alia on D1 (Melief et al., 2000, Adv. Immunol. 75: 235-282.) and based on the disclosures concerning the use of agonists of the 4-1BB molecule for anti-tumor therapy in D3 (Melero et al 1997, Nature Med 3, 682). As a result of these amendments, the present claims on which the IPER is based, no longer relate to the agonists of the 4-1BB molecule but instead relate exclusively to the anti-CD40 mono-therapy aspect of the application, which is inter alia based on the experiments in Example 12 of the application.

Since Mr Mittler did not contribute to these experiments or in any other way to this aspect of the invention his mention as an inventor would no longer be appropriate. The applicant therefore requests his deletion as an inventor and inventor/applicant from the above-identified International Application.

l'he representative,

Bart\Swinkels

DT03 Rec'd PCT/PTO 0 4 OCT 2004



IN RE APPLICATION OF:

ATTORNEY'S DOCKET NUMBER

Linda DIEHL, Geertje VAN MIERLO, Cornelis J. M. MELIEF, Rene TOES and Rienk OFFRINGA

0470-045183

PCT/NL03/00254

ENTITLED

"INDUCTION OF ANTI-TUMOR CTL IMMUNITY THROUGH IN VIVO TRIGGERING OF 4-1BB AND/OR CD40"

To MAIL STOP PCT
Attention: DO/EO/US
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

EXPRESS MAIL CERTIFICATE

"Express Mail" Label Number ____EV534966873US

Date of Deposit October 4, 2004

I hereby certify that the following attached papers or fees

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/
ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER
35 U.S.C. 371 (original and two (2) copies) and check in amount
of \$990.00 for filing fee and assignment recording fee
DECLARATION AND POWER OF ATTORNEY (4 pp.)
PRELIMINARY AMENDMENT with ABSTRACT
WO 03/084999 – FRONT PAGE with ABSTRACT, SPECIFICATION,
CLAIMS, DRAWINGS and SEARCH REPORT (63 pp.)
LETTER to WIPO withdrawing ROBERT S. MITTLER as an inventor (1 p.)
RECORDATION FORM COVER SHEET (1 p.) with ASSIGNMENT (3 pp.)

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA, 22313-1450.

Nora Ann Pastrick
(Typed name of person mailing paper or fee)

Nora Ann Pastrick
(Typed name of person mailing paper or fee)

Form PTO-1390U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE ATTORNEY'S DOCKET NUMBER (REV 10-95) 470-045183 TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371 INTERNATIONAL FILING DATE PRIORITY DATES CLAIMED INTERNATIONAL APPLICATION NO. PCT/NL03/00254 04.04.03 (April 4, 2003) 04.04.02 (April 4, 2002) Assignee: LEIDEN UNIVERSITY MEDICAL CENTER TITLE OF INVENTION INDUCTION OF ANTI-TUMOR CTL IMMUNITY THROUGH IN VIVO TRIGGERING OF 4-1BB AND/OR CD40 APPLICANT(S) FOR DO/EO/US Linda DIEHL, Geertje VAN MIERLO, Cornelis J.M. MELIEF, Rene TOES and Rienk OFFRINGA Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items 1. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. \square is transmitted herewith (required only if not transmitted by the International Bureau). b.
has been transmitted by the International Bureau. c. \square is not required, as the application was filed in the United States Receiving Office (RO/US). 6. A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. are transmitted herewith (required only if not transmitted by the International Bureau). b. \square have been transmitted by the International Bureau. c. \square have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 8.

A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. 🗌 A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11. to 16. Below concern document(s) or information included: 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A FIRST preliminary amendment. ☐ A SECOND or SUBSEQUENT preliminary amendment. 14. A substitute specification.

WO 03/084999 Front Page with Abstract, Specification, Claims, Drawings and Search Report (63 pp.)

15. A change of power of attorney and/or address letter.

Letter to WIPO withdrawing Robert S. Mittler as an inventor

16. Other items or information:

U.S. APPLICATI 9 (45-1-61-1 1 9		INTERNATIONAL APPLICATION NO. PCT/NL03/00254		ATTORNEY'S DOCKET NUMBER 470-045183	
17. ■ The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):				CALCULATIONS PTO USE ONLY	
Search Report has been prepared by the EPO or JPO					
International preliminary examination fee paid to USPTO (37 CFR 1.482) S750.00					
No international preliminary examination fee paid to USPTO (37 CFR 1.482) But international search fee paid to USPTO (37 CFR 1.445(a)(2))					
Neither international preliminary examination fee (37 CFR 1.482) nor International search fee (37 CFR 1.445(a)(2)) paid to USPTO					
International preliminary examination fee paid to USPTO (37 CFR 1.482) And all claims satisfied provisions of PCT Article 33(2)-(4)					•
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$ 950.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$ 0.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	14 - 20 =	0	X \$18.00	\$ 0.00	
Independent claims	1 - 3 =	0	X \$86.00	\$ 0.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$290.00				\$ 0.00	
TOTAL OF ABOVE CALCULATIONS =				\$ 950.00	
Reduction of 1/2 for filing by small entity, if applicable.				\$ 950.00	
SUBTOTAL =				\$ 950.00	
Processing fee of \$130.00 for furnishing the English translation later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(f)). +				\$ 0.00	
TOTAL NATIONAL FEE =				\$ 950.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$ 40.00	
TOTAL FEES ENCLOSED =				\$ 990.00	
				Amount to be: Refunded	\$
				Charged	\$
a. A check in the amount of \$_990.00_ to cover the above fees is enclosed.					
b. Please charge my Deposit Account No in the amount of \$ to cover the above fees. A duplicate copy of this sheet is enclosed.					
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 23-0650. A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO: William H. Logsdon 700 Koppers Building 436 Seventh Avenue Pittsburgh, Pennsylvania 15219-1818 Telephone: (412) 471-8815 Facsimile: (412) 471-4094 REGISTRATION NUMBER					